Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 1,764

Document Document Title
WO/2002/062351A1
A bisphosphonate for the treatment of osteonecrosis and/or osteonecrosis dissecans. The drug may further be used to prevent the onset of osteonecrosis and/or osteonecrosis dissecans and any complications associated with both diseases.  
WO2002016381B1
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject...  
WO/2002/060386A2
The present invention describes methods of preventing and treating inflammatory and immune-related diseases or disorders using inhibitors of I$g(k)B kinase (IKK). Also described are IKK inhibitors effective for the prevention and treatme...  
WO/2002/058730A2
Methods and compositions for the treatment of ocular neovascularization and macular degeneration. The invention includes combining photodynamic therapy with administration of a neuroprotectant and a neovascularization inhibitor.  
WO/2002/058750A2
A suspension of fibrinogen, thrombin, alcohol and optionally aprotinin is obtained by mixing fibrinogen in alcohol with thrombin in alcohol. The suspension contains fibrinogen and thrombin particles with a Folk Ward mean diameter of 25 -...  
WO/2002/058729A2
Methods of establishing hematopoietic chimerism useful to correct hematological diseases and promote acceptance of organ transplants include administering busulfan, costimulation blockade, and readily attainable numbers of T-cell deplete...  
WO/2002/058749A2
The present invention relates to a solid composition useful for tissue gluing, tissue sealing and haemostasis consisting essentially of a) a carrier which has at least one of the following physical properties: elasticity module in the ra...  
WO2000064911A9
The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates...  
WO/2002/053110A2
A preparation for douches and/or irrigations of natural or pathological cavities in the human body which comprises water added with at least one gaseous substance selected from carbon dioxide, oxygen, nitrogen, gaseous anaesthetic substa...  
WO/2002/053525A1
The inventive perfluoronated cycle-containing tertiary amines (PFCTA) of general formula (1) where n=1 or 2; m=2 or 3 X represents or , at n=2 X represents are used as a basis for gas conveying emulsions. PFCTA is a group of compounds ne...  
WO/2002/050039A1
Novel urea and urethane derivatives of general formula (I) in which R?1¿, R?2¿, R?3¿, R?5¿, R?5'¿, X, Y, B, m, n and o are as defined in Patent Claim 1, and physiologically acceptable salts or solvates thereof are integrin inhibitor...  
WO2000056350A9
The present invention provides methods that use agents capable of one or more of the following: inhibiting leukocyte mediated destruction of tissues, especially after injuries to tissue due to heat or cold (i.e., burns or frostbite), lig...  
WO/2002/048337A2
The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides meth...  
WO/2002/047721A1
The present invention provides anti-CD28 antibodies which are defective in mitogenic activity (silenced anti-CD28 antibodies), methods of producing, compositions containing the antibody and methods of immunosuppression, inducing T-cell t...  
WO/2002/047728A2
Posterior capsular opacification is inhibited by administration of polymer, having immobilised on the surface, a ligand for a death receptor, preferably joined by a spacer into the lens capsule following cataract surgery. The ligand is p...  
WO/2002/046148A1
The invention relates to anthranilic acids of formula (I) wherein the substituents R1-R3 have the designations cited in the claims. Said acids have no unwanted and detrimental salidiuretic properties, but rather very good cardioprotectiv...  
WO/2002/043785A2
Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an im...  
WO2002022112A9
This invention relates to the use of a PDE4 inhibitor or a pharmacologically acceptable salt thereof for manufacturing a medicament for preventing or treating a disease associated with an excess in IL-12 production.  
WO/2002/042248A2
The present invention relates to naphthalene derivatives of formula (I), wherein X is S, S(O), S(O)¿2?, S(O)¿2?NH, P(O)OCH¿3?, P(O)OH, NH, N(CH¿3?), NHC(O)NH, C(O), C(O)O, NHC(O), CH(OH), CH=N, CH=CH, CH¿2?NH, C(=NH); R?1¿ is aryl ...  
WO2001088103A9
The present invention is directed to methods and compositions to induce cellular dedifferentiation and tissue regeneration in vitro and in vivo.  
WO/2002/040476A1
Pyridyl substituted triazoles of formula (I): wherein R¿1? is naphthyl or phenyl optionally substituted with one or more substituents selected from the group consisting of halo, -O-C¿1-6?alkyl, -S-C¿1-6?alkyl, C¿1-6?alkyl, C¿1-6?hal...  
WO/2002/036751A2
A composition in human cord and placental blood which comprises unrestricted somatic stem cells is described here which can be amplified in vitro to large quantities sufficient for medical applications as regenerative medicines. Initiati...  
WO/2002/036771A2
The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascu lar endothelium.  
WO/2002/036162A2
Methods and compositions for the treatment of ocular neovascularization (CNV) and macular degeneration. The invention includes combining laser treatment with administration of a neuroprotectant.  
WO/2002/034250A1
Fat emulsions containing 2-phenoxyaniline derivatives represented by the general formula (1) wherein R?1¿ is hydrogen or lower alkoxy; R?2¿ is halogeno or nitro; and R?3¿ is hydrogen or halogeno. The fat emulsions make it possible to ...  
WO2001077137A9
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells tran...  
WO/2002/034202A2
An antioxidant compound is disclosed. The compound is characterized by (a) a peptide including at least three amino acid residues of which at least two are cysteine residues, each having a readily oxidizable sulfhydryl group for effectin...  
WO/2002/034258A1
The use of HETE derivatives in intraocular surgery (e.g., cataract surgery) is disclosed. The HETE derivatives protect and maintain the corneal endothelium.  
WO/2002/032900A2
This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y?1¿, Y?2¿, Y?3¿, and Y?4¿ are independently selected from N, CH, etc.; R?1¿ is H, C¿1-8? alkyl, etc.; Q?1¿ is a 5-12...  
WO/2002/032461A2
The present invention relates to novel conjugates between polypeptide variants of pro-tein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an ...  
WO/2002/032422A2
The invention features a method of treating rheumatoid arthritis in a mammal comprising administering an agent that inhibits prostaglandin EP4 receptor (EP4) activity. Also featured is a method of identifying agents that selectively inhi...  
WO/2002/032447A2
A composition for inhibiting cell damage comprising FR901459 Substance as following formula (I) or its salt in admixture with pharmaceutically acceptable carriers or excipients.  
WO/2002/030444A2
The present invention is directed to a method to prevent or reduce postoperative corneal subepithelial haze after excimer laser photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK) surgery. According to the method, a t...  
WO/2002/030446A2
Reducing or preventing adhesions which would form in a patient during or after surgery by administering to the wound surface of a patient a fibrinogen solution in an amount of about 0.025 ml fibrinogen/cm?2¿ to about 0.25 ml fibrinogen/...  
WO/2002/030445A2
Reducing or preventing adhesions which would otherwise form in a patient during or after surgery by administering a fibrinogen preparation containing a non-plasmin-acting fibrinolysis inhibitor such as eglin.  
WO/2002/030990A1
The present invention relates to water-insoluble, crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof, where the amide derivatives of hyaluronic acid are characterized by crosslinking, of polymer or oligomer...  
WO/2002/030485A1
It is intended to provide embolic materials which can be easily handled and have stable qualities. This object can be achieved by providing embolic materials containing polysaccharide ester derivatives having a weight-average molecular w...  
WO/2002/028817A1
The invention relates to substituted 1-aminobutan-3-ol derivatives, methods for the production thereof, pharmaceuticals containing said compounds and the use of substituted 1-aminobutan-3-ol derivatives for producing pharmaceuticals.  
WO/2002/026694A1
The invention relates to O-substituted 6-methyl-tramadol derivatives, to methods for producing them, to medicaments containing these compounds and to the use of O-substituted 6-methyl-tramadol derivatives for producing medicaments for tr...  
WO/2002/026935A2
A family of small peptides have been found to be inhibitory to TGF-$g(b) activity, and preferably have the primary structure of Formula (1): AA¿1?-AA¿2?-AA¿3?-Pro-D-Glu-Ala, wherein AA¿1? is leucine, phenylalanine, $g(a)-aminoisobutr...  
WO/2002/024218A1
The invention concerns the use of a compound of formula (I), wherein: A¿1? is the radical corresponding to D- or L-Ser; A¿2? is the radical corresponding to D- or L-Asp or Glu; A¿3? is the radical corresponding to D- or L- Lys, Arg or...  
WO/2002/022611A2
Described herein are compounds that are useful as caspase inhibitors having the formula (I):wherein Ring A is an optionally substituted piperidine, tetrahydorquinoline or tetrahydroisoquinoline ring; R?1¿ is hydrogen, CN, CHN?2¿, R, or...  
WO/2002/020005A1
A method for facilitating an in vivo procedure on an internal region of the body of a human subject, which region comprises muscle, wherein there is administered to part or all of the said region, before or during the procedure, arginine...  
WO/2002/017878A1
Lung surfactant compositions capable of forming a dynamic swelling phase when dispersed in a medium containing electrolytes. The dynamic swelling process can be observed by polarising microscopy and results in formation of a birefringere...  
WO2001079271A9
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells tran...  
WO/2002/016328A1
The invention relates to novel biphenyl derivatives of the general formula (I), wherein R?4¿ represents an aromatic heterocycle, and to the physiologically acceptable salts or solvates thereof. The inventive compounds are integrin inhib...  
WO2001079258A9
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells tran...  
WO/2002/015913A1
Provided is a method of treating an area affected by a trauma, such as a corneal wound or internal trauma, comprising administering to the affected area a trauma treating effective amount of a composition comprising a polyanionic polymer.  
WO/2002/014320A2
The invention relates to novel compounds which bind to integrin receptors, in particular as ligands for the $g(a)¿V?$g(b)¿3? integrin receptor, the use thereof and pharmaceutical preparations containing said compounds.  
WO/2002/014350A2
The invention relates to compounds of formula (I) B-Q-X¿1?, wherein B is a bioactive, cell adhesive mediating molecule, selected from the group (i) and Thr-Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Arg-Asn-Arg-Lys (ii), Trp-Tyr-Lys-Ile-Ala-Phe-Gln-Ar...  

Matches 401 - 450 out of 1,764